Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.91 USD | -2.82% |
|
-3.09% | -9.38% |
| Jul. 17 | Nordic stocks in North America - Astra Zeneca fell 0.3% | FW |
| Jul. 16 | Nordic stocks in North America, Autoliv fell 1.6 percent | FW |
| Market Cap | 113B 17.31B 15.17B 14.02B 12.9B 24.33B 1,669B 24.72B 168B 65.72B 817B 64.98B 63.57B 2,813B | P/E 2026 * |
24.1x | P/E 2027 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise Value | 133B 20.26B 17.76B 16.41B 15.09B 28.48B 1,953B 28.94B 196B 76.93B 956B 76.07B 74.41B 3,293B | EV / Sales 2026 * |
4.73x | EV / Sales 2027 * | 3.79x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -2.82% | ||
| 1 week | -3.09% | ||
| Current month | +1.60% | ||
| 1 month | +10.45% | ||
| 6 months | -10.92% | ||
| Current year | -9.38% |
| 1 week | 27.86 |  | 29.29 |
| 1 month | 24.88 | | 29.8 |
| Current year | 23.62 | | 35.43 |
| 1 year | 21 | | 35.43 |
| 3 years | 17.24 | | 42.72 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.82% | -3.09% | - | - | 17.56B | |
| +0.21% | -0.79% | +53.17% | +57.39% | 53.83B | |
| +5.37% | +3.31% | +50.39% | +83.65% | 52.1B | |
| -1.20% | -1.94% | +4.35% | +402.68% | 23.48B | |
| +0.74% | +2.32% | -16.23% | -14.44% | 23.13B | |
| 0.00% | 0.00% | +36.43% | -6.14% | 19.36B | |
| -1.67% | -6.00% | +163.95% | +284.69% | 15.2B | |
| -0.69% | +0.46% | +32.55% | +571.81% | 14.83B | |
| -0.70% | -0.91% | +24.87% | +179.47% | 14.06B | |
| -3.21% | +0.88% | +60.32% | +151.29% | 12.76B | |
| Average | -0.41% | -1.50% | +45.53% | +190.04% | 25.42B | |
| Weighted average by Cap. | +0.57% | -1.48% | +43.78% | +147.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.06B 4.28B 3.75B 3.47B 3.19B 6.02B 413B 6.12B 41.49B 16.27B 202B 16.08B 15.73B 696B | 33.02B 5.04B 4.42B 4.08B 3.76B 7.09B 486B 7.2B 48.82B 19.14B 238B 18.92B 18.51B 819B |
| Net income | 4.76B 726M 636M 588M 541M 1.02B 70B 1.04B 7.03B 2.76B 34.25B 2.73B 2.67B 118B | 7.08B 1.08B 947M 876M 805M 1.52B 104B 1.54B 10.47B 4.11B 51B 4.06B 3.97B 176B |
| Net Debt | 19.34B 2.95B 2.59B 2.39B 2.2B 4.15B 285B 4.22B 28.59B 11.21B 139B 11.08B 10.84B 480B | 11.8B 1.8B 1.58B 1.46B 1.34B 2.53B 174B 2.57B 17.44B 6.84B 84.96B 6.76B 6.61B 293B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-20 | $27.91 | -2.82% | 1,245,539 |
| 26-07-17 | $28.72 | -0.90% | 2,629,330 |
| 26-07-16 | $28.98 | -0.34% | 1,568,350 |
| 26-07-15 | $29.08 | +1.22% | 1,744,239 |
| 26-07-14 | $28.73 | -0.24% | 1,633,339 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
